Reviewed by a board-certified obesity medicine physician. Last updated March 2026.

What Are GLP-1 Medications?

GLP-1 receptor agonists are a class of prescription medications that mimic a natural gut hormone called glucagon-like peptide-1. Originally developed for type 2 diabetes, these drugs have demonstrated significant weight loss in large clinical trials [1]. As of early 2026, approximately 18% of U.S. adults report having tried a GLP-1 medication for weight loss or diabetes management, according to KFF polling data [2].

Good to Know

This guide provides an overview of GLP-1 medications for weight loss. It is a starting point for your research, not a substitute for personalized medical advice. Always consult with a qualified healthcare provider before starting any medication.

Key Takeaways
  • Two GLP-1 medications hold FDA approval for chronic weight management: semaglutide (Wegovy) at up to 2.4 mg weekly and tirzepatide (Zepbound), a dual GIP/GLP-1 agonist approved in November 2023.
  • In the SURMOUNT-5 direct head-to-head trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks, the most definitive comparison available.
  • FDA labeling requires a BMI of 30 or higher, or 27 or higher with a weight-related condition like hypertension or type 2 diabetes, before a prescriber can authorize GLP-1 treatment for weight loss.
  • Brand-name GLP-1 injectables list at $1,000 to $1,650 per month, but LillyDirect vials and telehealth cash-pay programs bring self-pay costs to $149 to $499 per month depending on the medication.
  • Using FSA or HSA funds for GLP-1 medications effectively saves patients 20 to 35% depending on tax bracket, a meaningful reduction on treatment that can run thousands of dollars per year.

The medications work through three primary mechanisms. First, they act on appetite centers in the hypothalamus to reduce hunger and increase satiety. Second, they slow gastric emptying, which means food stays in the stomach longer and you feel full after smaller portions. Third, they improve insulin sensitivity and blood sugar regulation, which reduces cravings driven by glucose fluctuations.

FDA-Approved Options for Weight Loss

Two GLP-1 medications currently hold FDA approval specifically for chronic weight management in adults.

[Semaglutide](/medications/semaglutide-injection) (Wegovy)

Wegovy received FDA approval for weight management in June 2021 [3]. It is administered as a weekly subcutaneous injection at doses up to 2.4 mg. In the STEP 1 trial, participants without diabetes lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo [1]. An oral tablet formulation of semaglutide for weight loss received FDA approval in December 2025, expanding options for patients who prefer not to inject.

[Tirzepatide](/medications/tirzepatide) (Zepbound)

Zepbound earned FDA approval for weight management in November 2023 [4]. Unlike semaglutide, tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin hormone pathways simultaneously. In the SURMOUNT-1 trial, the highest dose produced average weight loss of 22.5% over 72 weeks [5]. The SURMOUNT-5 trial, a direct head-to-head comparison, showed tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks [6].

Other GLP-1 Medications

Liraglutide (Saxenda) was the first GLP-1 approved for weight loss in December 2014, but produces more modest results (5-10% body weight). Ozempic (semaglutide 2.0 mg) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, not weight loss, though physicians may prescribe them off-label.

Who Qualifies?

FDA labeling specifies GLP-1 weight loss medications for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. Your provider will also screen for contraindications including personal or family history of medullary thyroid carcinoma, MEN2 syndrome, and pregnancy.

What Does Treatment Cost?

Cost remains the biggest barrier to GLP-1 access. Approximately 56% of current and former GLP-1 users report affordability challenges [2].

List prices range from $1,000 to $1,650 per month for branded injectable formulations. However, actual out-of-pocket costs vary widely:

  • Wegovy: NovoCare offers a direct cash-pay program at $499/month. The new oral Wegovy tablet is available at $149 to $299/month through select pharmacies.
  • Zepbound: LillyDirect sells single-dose vials at $299 to $449/month, depending on dose, for self-pay patients.
  • With commercial insurance: Copays typically range from $25 to $150/month when using manufacturer savings cards.
  • Medicare: Does not cover GLP-1 medications for weight loss as of 2026. Coverage for diabetes indications (Ozempic, Mounjaro) is available under Part D.
  • Medicaid: Only 13 states currently cover GLP-1 medications for obesity [7].
Good to Know

GLP-1 medications require a prescription and ongoing medical supervision. Always work with a licensed healthcare provider and verify that any telehealth platform or clinic uses board-certified clinicians and accredited pharmacies.

Insurance and Cost Considerations

The cost of GLP-1 medications varies dramatically depending on whether you use brand-name or compounded options. Brand-name Wegovy runs approximately $1,349 per month without insurance, while compounded semaglutide from telehealth providers starts at $149 per month.

If you have private insurance, check whether your plan covers GLP-1 medications. Many insurers now require prior authorization but will cover Wegovy or Zepbound with a copay of $25 to $50 per month when combined with a manufacturer savings card.

For self-pay patients, FSA and HSA funds can be used for GLP-1 medications prescribed for obesity or type 2 diabetes, effectively saving 20% to 35% on out-of-pocket costs.

Safety and Side Effects Overview

The most common side effects across all GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These typically improve during the dose titration schedule as your body adjusts.

⚠️Important

GLP-1 medications are not suitable for patients with a personal or family history of medullary thyroid cancer, a history of pancreatitis, or Multiple Endocrine Neoplasia syndrome type 2. Always discuss your full medical history with your provider before starting treatment.

All GLP-1 medications require a prescription and ongoing medical supervision. Regular follow-up appointments and blood tests help monitor for side effects like hypoglycemia and ensure the medication is working effectively.

Finding a Provider

Qualified GLP-1 providers include board-certified obesity medicine specialists (ABOM), endocrinologists, internal medicine physicians, and family medicine physicians with weight management experience. Look for clinics that conduct proper medical evaluations before prescribing, offer ongoing monitoring, and provide transparent pricing.

Browse verified providers in our GLP-1 clinic directory to compare credentials, pricing, and patient reviews in your area.

Ready to start your weight loss journey? Find a GLP-1 clinic near you and connect with a qualified provider today.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication.

Sources

  1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  2. KFF Health Tracking Poll, May 2024. "Public Opinion on GLP-1 Drugs for Weight Loss." https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/
  3. FDA. Wegovy (semaglutide) Approval Letter. June 4, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/215256Orig1s000ltr.pdf
  4. FDA. "FDA Approves New Medication for Chronic Weight Management." November 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  5. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  6. Aronne LJ, et al. "Tirzepatide vs Semaglutide for Weight Loss in Adults with Obesity." SURMOUNT-5 Trial. ClinicalTrials.gov NCT05822609. https://clinicaltrials.gov/study/NCT05822609
  7. KFF. Medicaid Coverage of and Spending on GLP-1s. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/